

## International Conference on CANCER THERAPY & International Conference on

Oliver L et al., J Clin Exp Oncol 2018, Volume: 7 DOI: 10.4172/2324-9110-C3-014

## VACCINES & VACCINATION


July 23-24, 2018 | Osaka, Japan

## **DECONSTRUCTION – RECONSTRUCTION of the tumour**

Oliver L<sup>1,2,3</sup>, Geraldo F<sup>1,2</sup>, Vallette FM<sup>1,2</sup> <sup>1</sup>Universite de Nantes, France <sup>2</sup>University of Nantes, France <sup>3</sup>Hopital de Nantes, France

ur group works on Glioblastoma Multiforme (GBM) tumours. In collaboration with neurosurgeons we obtain tumours from the tumorotheque, which are disassociated mechanically with the aim of recuperating all the cells present in the tumour. It is well known that the Glioblastoma consists of a heterogeneous cell population and our culture conditions allow for the proliferation and survival of all the cell types present in the original tumour. This first part would represent the deconstruction of the tumour and at present we have at our disposition a collection of 80 primary cultures of GBMs. Initial experiments have shown that in the present of "Cancerassociated Fibroblasts" or CAFs, tumour cells proliferate more and respond less to irradiation and temolozolamide (TMZ) (principal treatment for GBM). For the second part of our project namely the "reconstruction" we have developed a system of 3D-bioprinting, which would include adding a mixture of primary GBM cells and CAFs in a matrix of hydrogel and collagen that would represent our bioink. Using a 3D-bioprinter we would then reconstruct the tumour. The reconstructed tumour scaffolds should all be identical and contain similar cell numbers that are important

in the analyses. Once tumour cell aggregates are visible in the scaffolds, these scaffolds would be used to determine the role of CAFs in the "protection – survival" of the tumour after chemo- (100  $\mu$ M TMZ) and/or radiotherapy.



## **Biography**

L. Oliver completed her PhD at the University of Paris VII, France. Presenting working in the group of Dr Francois Vallette at "Centre of Research in Cancer-Immunology Nantes-Angers". She has published over 80 articles in reputed journals.

Lisa.Oliver@univ-nantes.fr